Genflow Biosciences PLC (LON: GENF) has submitted a formal request for examination of its patent application in China relating to proprietary SIRT6 variants designed for the treatment of Non-Alcoholic Steatohepatitis (NASH), a severe and progressive liver disease.
The filing strengthens Genflow’s global intellectual property portfolio and underlines its commitment to developing innovative, gene-based therapies.
The company believes its SIRT6-based therapies have the potential to transform the treatment landscape for NASH, addressing a condition with significant unmet medical need.
Dr. Eric Leire, CEO of Genflow, commented: “The filing of this examination request in China represents another significant step in protecting our technology in one of the world’s largest healthcare markets. We are committed to advancing our research into SIRT6-based therapies and believe that our approach holds strong potential to transform the treatment landscape for NASH.
About Genflow Biosciences
Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow’s lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow’s 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs planned for 2025, include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit www.genflowbio.com and follow the Company on LinkedIn and X.
